NCT04713709已完成1 期
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder and Narcan® 4 mg/0.1 mL Nasal Spray Under Fasting Conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Nasus Pharma
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- Unconjugated naloxone in plasma - Tmax
研究概览
简要总结
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Nasal Powder.
详细描述
A comparison between FMXIN001 4 mg and Narcan® 4 mg/0.1 mL Nasal Spray under Fasting Conditions. A pharmacokinetic study in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, non-smoking, male and female subjects, 18 years of age or older.
- •BMI ≥18 and ≤30 kg/m
- •Females may be of childbearing or non-childbearing potential:
- •Childbearing potential:
- •o Physically capable of becoming pregnant
- •Non-childbearing potential:
- •Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or
- •Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause).
- •Willing to use acceptable, effective methods of contraception.
- •Able to tolerate venipuncture.
- •Be informed of the nature of the study and give written consent prior to any study procedure.
排除标准
- •The following exclusion criteria will be assessed at screening (within 28 days prior to the first drug administration):
- •Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •Known or suspected carcinoma.
- •Known history or presence of hypersensitivity or idiosyncratic reaction to naloxone or any other drug substances with similar activity.
- •Known history or presence of clinically significant lactose, galactose, or fructose intolerance.
- •Presence of hepatic or renal dysfunction.
- •Presence of nostril or septum piercing.
- •Presence of abnormal nasal anatomy.
- •Presence of hay fever/seasonal allergy/rhinitis.
- •Presence of sinusitis.
- •Presence of nasal symptoms (e.g., blocked and/or runny nose, nasal polyps).
- •Presence of nasal septum ulcers or perforations, or nasal trauma within 30 days prior to drug administration.
- •History of nasal surgery.
- •History of malabsorption within the last year or presence of clinically significant gastrointestinal disease.
- •History of atopic allergy (e.g., asthma, urticaria, eczematous dermatitis).
- •Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
- •History of drug or alcohol addiction requiring treatment.
- •Any acute illness (e.g., cold/ rhinitis, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration.
- •Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- •Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
- •Difficulty fasting or consuming standard meals.
- •Inability to communicate well with the Investigators and staff (i.e., language problem, poor mental development or impaired cerebral function).
- •Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
- •Females who:
- •Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to drug administration;
- •Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration;
- •Are pregnant (serum hCG consistent with pregnancy); or
- •Are lactating.
- •Donation or loss of whole blood (including clinical trials):
- •≥50 mL and <500 mL within 30 days prior to drug administration;
- •≥500 mL within 56 days prior to drug administration.
- •Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
- •On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
- •Have had a tattoo or body piercing within 30 days prior to drug administration.
- •Have clinically significant findings in vital signs measurements.
- •Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic blood pressure decrease in value by more than 10 mmHg from supine or sitting to standing position.
- •Have clinically significant findings in a 12-lead ECG.
- •Have clinically significant abnormal laboratory values.
- •Have significant diseases.
- •Have clinically significant findings from a physical examination.
- •Use of any enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism or alter gastrointestinal pH/movement (e.g., omeprazole, ranitidine) within 30 days prior to drug administration.
结局指标
主要结局
Unconjugated naloxone in plasma - Tmax
时间窗: 0 to 8 hours post dose
Pharmacokinetic Parameters
Unconjugated naloxone in plasma- T half
时间窗: 0 to 8 hours post dose
Pharmacokinetic Parameters
Unconjugated naloxone in plasma - K el
时间窗: 0 to 8 hours post dose
Pharmacokinetic Parameters
Unconjugated naloxone in plasma - Cmax
时间窗: 0 to 8 hours post dose
Pharmacokinetic Parameters
Unconjugated naloxone in plasma - AUC
时间窗: 0 to 8 hours post dose
Pharmacokinetic Parameters
次要结局
- 12-Lead ECG(12 hours)
- Blood pressure(12 hour post dose)
- Pulse(12 hour post dose)
- Nasal examination(23 hour)
- Adverse events(0 to 24 hour post dose)
- 4-item NHANES Pocket Smell Test(24 hours post dose)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Comparative Bioavailability of Intranasal EpinephrineAnaphylaxisAnaphylactic ReactionNCT06205134Nasus Pharma12
尚未招募
1 期
Single-Dose, Fed Bioequivalence Study of MYLAN Rivaroxaban Tablets 20 mg (20 mg; Mylan) and Xarelto® 20 mg (20 mg; Bayer) in Healthy Adult VolunteersBioequivalence Study,Healthy,Thai VolunteersRivaroxaban ,TCTR20201224002International Bio Service Co.,Ltd.36
尚未招募
1 期
Single-Dose, Fed Bioequivalence study of Mylan Esomeprazole 40 mg DR tablets; Mylan Laboratories Limited, India relative to Nexium® 40 mg tablets of AstraZeneca in healthy Thai volunteersBioequivalence studyEsomeprazoleTCTR20200630001Bio-innova and Synchron.Co.,Ltd48
已完成
1 期
Bioavailability of Nasal EpinephrineAnaphylaxisNCT04696822Nasus Pharma12
已完成
不适用
Bioequivalecne Study of Minocycline 100mg Tablets Under Fed ConditionsHealthyNCT00777413Ranbaxy Laboratories Limited24